FDA SaMD risk categories, OUD guidance in 2021?

Issue 074

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week I wrote about Germany's first two reimbursed prescription digital therapeutics and how pharma execs think digital products should be priced. Here's what's happening this week:

(OK, this was earlier in the month but) Fitbit quietly snagged a $900,000 contract with the Department of Veterans

Paying Subscribers Only

It's a good one, too.

This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

FDA SaMD risk categories, OUD guidance in 2021?

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

New! E&O's free weekly newsletter.